Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01238393
NCT01238393
Completed
Not Applicable

A Prospective Pilot Study of Lucentis for Epiretinal Membranes: the LERM Study

Queen's University1 site in 1 country11 target enrollmentNovember 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsEpiretinal Membrane
Interventionsintravitreal ranibizumab
Drugsintravitreal ranibizumab

Overview

Phase
Not Applicable
Intervention
intravitreal ranibizumab
Conditions
Epiretinal Membrane
Sponsor
Queen's University
Enrollment
11
Locations
1
Primary Endpoint
Evidence of improvement measured by optical coherence tomography
Status
Completed
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSitesSimilar Trials

Overview

Brief Summary

The purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.

Registry
clinicaltrials.gov
Start Date
November 2010
End Date
January 2012
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •symptomatic idiopathic epiretinal membrane

Exclusion Criteria

  • •vision worse than 6/18 and fit for surgery
  • •prior vitreoretinal surgery or injection
  • •any past or current form of retinal vein occlusion or neovascularization
  • •age-related macular degeneration
  • •other condition causing significant limitation of visual potential

Arms & Interventions

Ranibizumab

('intravitreal ranibizumab' )

Intervention: intravitreal ranibizumab

Outcomes

Primary Outcomes

Evidence of improvement measured by optical coherence tomography

Time Frame: 3 and 6 months

Secondary Outcomes

  • Subjective change in symptoms(3 and 6 months)
  • Amsler grid improvement(3 and 6 months)
  • Near visual acuity (Snellen)(3 and 6 months)
  • Distance visual acuity (ETDRS)(3 and 6 months)
  • Quality of life improvement(6 months)

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 1
Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel GrowthNeovascularization
NCT00685503National Eye Institute (NEI)1
Completed
Phase 1
Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel GrowthMacular Telangiectasia
NCT00685854National Eye Institute (NEI)5
Completed
Phase 2
Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)Vitreous HemorrhageProliferative Diabetic Retinopathy
NCT00996437Jaeb Center for Health Research261
Completed
Phase 1
Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel FormationTelangiectasia
NCT00457145National Eye Institute (NEI)5
Completed
Phase 1
Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel FormationTelangiectasia
NCT00457067National Eye Institute (NEI)5